Application of Real-World Evidence in Selecting CAR T in R/R MM

EP: 1.Welcome to This OncLive Peer Exchange: Highlighting Key Abstracts From ASH 2024

EP: 2.Insights From the Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

Now Viewing

EP: 3.Application of Real-World Evidence in Selecting CAR T in R/R MM

EP: 4.Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

EP: 5.Choosing Between Bispecifics and CAR T: Real-World Implications in R/R MM

EP: 6.Future of Bispecifics and CAR T in R/R MM

EP: 7.Overview of the 5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in R/R Indolent NHL

EP: 8.Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial

EP: 9.Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

EP: 10.Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study

EP: 11.Implications of BTK Inhibitors Combined With CAR-T in R/R CLL/SLL

EP: 12.Overview of ZUMA-2 Cohorts 1-3: Use of Brexu-cel in R/R MCL

Video content above is prompted by the following:

Chimeric Antigen Receptor (CAR) T-Cell Therapy in R/R MM

Panelists discuss how real-world comparative analyses reveal nuanced differences in the efficacy and safety profiles of ciltacabtagene autoleucel and idecabtagene vicleucel among patients with R/R MM, highlighting the critical importance of translating clinical trial data into practical treatment strategies.

Key Insights from Real-World Analysis

The retrospective intention-to-treat analysis by Amoozgar et al presented at ASH 2024 (abstract #2408) offers several important perspectives:

Real-World Efficacy Variations: Real-world studies demonstrate that CAR T-cell therapy outcomes can differ significantly from controlled clinical trial settings due to patient heterogeneity, comorbidities, and prior treatment histories.

Comparative Performance: The study likely compared the efficacy and safety of 2 different CAR T-cell therapies (ciltacabtagene autoleucel and idecabtagene vicleucel) in actual clinical practice.

Patient Selection Implications: Real-world data help refine patient selection criteria and predict more personalized treatment responses beyond initial clinical trial parameters.

Safety Profile Nuances: The analysis would have shed light on potential adverse events, treatment-related complications, and long-term tolerability in a more diverse patient population.